DCM
AGRX

DG Capital Management’s Agile Therapeutics AGRX Stock Holding History

DG Capital Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-110
Closed -$634K – 133
2020
Q4 		$634K Sell
110
-433
-80% -$2.55M 0.27% 34
2020
Q3 		$3.3M Buy
543
+146
+37% +$837K 1.99% 21
2020
Q2 		$2.21M Buy
397
+282
+245% +$1.47M 1.81% 22
2020
Q1 		$428K Buy
+115
New +$660K 0.68% 15

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return

DG Capital Management's AGRX Position: Q1 2021 in Review

DG Capital Management sold out of Agile Therapeutics (AGRX) in Q1 2021, closing a stake of 110 shares — an estimated $634K sold.

DG Capital Management first reported a position in AGRX in Q1 2020 and held it in 4 quarters. The position peaked at $3.3M in Q3 2020. 73 funds tracked by Wall St. Rank hold AGRX as of Q1 2021.

  • DG Capital Management reported no remaining Agile Therapeutics position as of Q1 2021 after selling out during the quarter.
  • DG Capital Management sold 110 Agile Therapeutics shares in Q1 2021, an estimated $634K.
  • DG Capital Management first reported a position in Agile Therapeutics in Q1 2020 and held it in 4 quarters.
  • DG Capital Management's Agile Therapeutics position peaked at $3.3M in Q3 2020.
  • 73 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2021.

Based on DG Capital Management's 13F filing for Q1 2021, filed 13 May 2021.